Objectives and sensing systems
SENSOPAD project’s objectives are not just about developing novel sensor systems and technologies. By integrating state-of-the-art tools with patient empowerment, SENSOPAD stands to make a significant impact in the fight against this challenging condition.
Develop innovative biodegradable pads with smart absorption
SENSOPAD will develop biodegradable pads with smart absorption capabilities. These pads will integrate bio-based nanofibers and super absorbent polymers (SAPs) for superior absorption while also embedding smart sensors that detect key biomarkers related to endometriosis.
01
Development of the sensoPAD
One of the core elements of the project is the development of sensoPAD, a wearable sensor embedded in a sanitary pad for non-invasive biomarker detection. sensoPAD features three Biological Processing Units (BPUs), combining electrochemical sensors (EC), Radio Frequency Identification (RFID), and a chemical-based fuel cell to detect and quantify pro-inflammatory and anti-inflammatory endometriosis-related (ED) proteins. By utilising advanced electrochemical and colorimetric analysis techniques of the menstrual fluids, sensoPAD aims to enhance diagnostic precision and facilitate early intervention, even in asymptomatic women.
02
Development of the SensoMFgFET
Another matter of great significance is the development of a portable point-of-care device, which combines a microfluidic (MF) system with graphene-based biosensors to detect specific DNA Single Nucleotide Polymorphisms (SNPs) in menstrual fluid. Equipped with RFID technology, it securely transmits data for real-time analysis, providing autonomy to clinical practitioners
03
Wireless biomarker detection with graphene sensors
Another objective is the integration of graphene Field-Effect Transistors (gFET) into pads and wearable sensors for real-time, wireless detection of endometriosis biomarkers, enabling non-invasive, early diagnosis and personalized health monitoring
04
Conduct clinical and consumer validation studies
To ensure effectiveness, accuracy and user acceptance, the project partners will conduct clinical and consumer validation studies, refining SENSOPAD’s solutions based on real-world feedback from patient organisations and healthcare professionals.
05
Ensure market readiness and compliance with regulatory standards
The technological development process will strictly adhere to regulatory requirements for safe and effective use. In addition, market research, business modelling and business planning studies will aim to ensure the market readiness for our innovative solutions.
06
Create a user-friendly mobile app for data visualisation and AI-driven analytics for personalised insights
The mobile app will collect real-time biomarker data from the sensors and visualize key health indicators related to menstrual health and endometriosis. It will provide continuous tracking, empowering users to manage their health proactively and facilitate early intervention when needed.
07
Enhance patient empowerment
By providing knowledge on endometriosis, supporting informed decision-making through its sensing tools, and enabling active participation in disease management, SENSOPAD aims to empower women to take control of their health, enhancing autonomy and well-being while reducing the burden of managing endometriosis.
08
Sensing SYSTEMS
SensoPAD
SensoPAD is an innovative self-monitoring menstrual pad designed for early, non-invasive detection of endometriosis (ED). Unlike traditional methods that require lab tests or medical procedures, SensoPAD incorporates three BioProcessing Units (BPUs) within the pad to detect ED-related inflammatory proteins on menstrual fluids. These BPUs can identify elevated cytokines, which are key biomarkers for endometriosis, providing real-time insights into a woman’s health.
The goal is to develop an affordable and eco-friendly product that allows women to monitor their health at home, from menarche to menopause. By offering self-monitoring capabilities, SensoPAD makes it easier to identify endometriosis early, without the need for invasive procedures. It represents a significant leap beyond current menstrual products by combining advanced materials with smart sensors for early diagnosis and better health management.
SensoMFgFET
SensoMFgFET combines graphene Field-Effect Transistor (gFET) technology with CRISPR-based DNA analysis to provide a powerful diagnostic tool for endometriosis. This Point-of-Care (POC) device enables clinicians to detect Single-Nucleotide Polymorphisms (SNPs) associated with endometriosis, directly from menstrual blood.
Unlike traditional methods such as laparoscopy or MRI, which are costly and invasive, SensoMFgFET offers a compact, cost-effective solution. The device uses CRISPR-gFET sensors to extract and analyze DNA, providing accurate results quickly and with a much smaller footprint. It is set to revolutionize the way endometriosis is diagnosed, making it accessible and efficient for both developed and developing countries.